Home » Stocks » Pacira Biosciences

Pacira Biosciences, Inc. (PCRX)

Stock Price: $61.22 USD 1.26 (2.10%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.62B
Revenue (ttm) 408.30M
Net Income (ttm) -10.09M
Shares Out 42.74M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE 32.26
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $61.22
Previous Close $59.96
Change ($) 1.26
Change (%) 2.10%
Day's Open 60.36
Day's Range 59.81 - 61.29
Day's Volume 738,283
52-Week Range 27.46 - 62.25

More Stats

Market Cap 2.62B
Enterprise Value 2.69B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.74M
Float 39.94M
EPS (basic) -0.25
EPS (diluted) -0.25
FCF / Share 0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.50%
Payout Ratio n/a
Shares Short 6.50M
Short Ratio 10.20
Short % of Float 27.01%
Beta 1.28
PE Ratio n/a
Forward PE 32.26
P/FCF Ratio 199.40
PS Ratio 6.41
PB Ratio 6.43
Revenue 408.30M
Operating Income 14.07M
Net Income -10.09M
Free Cash Flow 13.12M
Net Cash -68.90M
Net Cash / Share -1.61
Gross Margin 59.32%
Operating Margin 3.45%
Profit Margin -2.50%
FCF Margin 3.21%
ROA 2.45%
ROE -2.76%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (14)

Buy 9
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$63.54*
(3.79% upside)
Low
54.0
Current: $61.22
High
85.0
Target: 63.54
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue42133728727624919885.5539.0815.6914.56
Revenue Growth24.83%17.67%3.71%10.99%25.97%131.05%118.89%149.12%7.74%-
Gross Profit31425019916617712030.786.95-1.052.29
Operating Income10.4815.92-24.94-32.029.46-5.17-53.29-49.30-39.10-22.71
Net Income-11.02-0.47-42.61-37.951.86-13.72-63.91-52.28-43.33-27.15
Shares Outstanding41.5140.9139.8137.2436.5435.3033.1830.3316.440.57
Earnings Per Share-0.27-0.01-1.07-1.020.04-0.39-1.93-1.72-2.64-47.29
Operating Cash Flow70.5248.8717.7933.4528.0226.56-43.84-70.13-31.00-24.88
Capital Expenditures-10.16-14.51-19.27-24.71-40.30-22.98-12.17-18.26-6.15-6.77
Free Cash Flow60.3634.36-1.488.74-12.273.58-56.01-88.39-37.15-31.65
Cash & Equivalents29238331117315915873.7942.5777.4527.45
Total Debt35229127610910410398.9625.1925.5874.85
Net Cash / Debt-59.9792.5234.8563.8654.9355.07-25.1817.3851.88-47.40
Assets83168962839138832617011211366.56
Liabilities47636834917216915512946.2065.22115
Book Value35532127921921817141.2565.8648.27-48.38
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pacira Biosciences, Inc.
Country United States
Employees 606
CEO David M. Stack

Stock Information

Ticker Symbol PCRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: PCRX
IPO Date February 3, 2011

Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.